<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425814</url>
  </required_header>
  <id_info>
    <org_study_id>M/100977/25</org_study_id>
    <secondary_id>LBC25</secondary_id>
    <nct_id>NCT01425814</nct_id>
  </id_info>
  <brief_title>Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population</brief_title>
  <official_title>A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Strengths of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single
      doses of inhaled LAS100977 in COPD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Day 2</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1 At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalised Forced Expiratory Volume in One Second (FEV1) Area Under the Curve</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Forced Expiratory Volume in One Second (FEV1) Values</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Day 1</time_frame>
    <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Forced Vital Capacity (FVC)</measure>
    <time_frame>Day 2</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1 At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalised Forced Vital Capacity (FVC) Area Under the Curve</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC)</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Forced Vital Capacity (FVC) Values</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Forced Vital Capacity (FVC)</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Forced Vital Capacity (FVC)</measure>
    <time_frame>Day 1</time_frame>
    <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inspiratory Capacity (IC)</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Inspiratory Capacity (IC) Values</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Arm #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977</intervention_name>
    <description>Dry powder inhalation,Once daily, single dose</description>
    <arm_group_label>Arm #1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977</intervention_name>
    <description>Dry powder inhalation,Once daily, single dose</description>
    <arm_group_label>Arm #2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977</intervention_name>
    <description>Dry powder inhalation,Once daily, single dose</description>
    <arm_group_label>Arm #3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977</intervention_name>
    <description>Dry powder inhalation,Once daily, single dose</description>
    <arm_group_label>Arm #4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference</intervention_name>
    <description>Dry powder inhalation (capsule),single dose</description>
    <arm_group_label>Arm #5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose</description>
    <arm_group_label>Arm #6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and non-pregnant, non-lactating females aged 40 or older.

          2. Patients with a clinical diagnosis of COPD, according to the GOLD guidelines and
             stable airway obstruction.

          3. Patients with a post-salbutamol FEV1 equal to or greater than 30% of the predicted
             value and less than 80% of the predicted value

          4. Post-salbutamol FEV1/FVC &lt; 70% at screening visit.

          5. Pre-dose FEV1 value of first treatment period within the range of 80-120% of the FEV1
             measured at screening prior to salbutamol inhalation.

          6. Current, or ex-cigarette smokers (former) with a smoking history of at least 10
             pack-years.

          7. Patients whose COPD symptoms at the time of randomisation are stable compared to the
             Screening visit, according to the investigator's medical judgment.

        Exclusion Criteria:

          1. History or current diagnosis of asthma.

          2. A respiratory tract infection or COPD exacerbation in the six weeks prior to the
             screening visit.

          3. Patients who have been hospitalised for an acute COPD exacerbation in the 3 months
             prior to screening visit.

          4. Clinically significant respiratory conditions other than COPD condition.

          5. Clinically significant cardiovascular conditions.

          6. Patients unable to properly use a dry powder or pMDI inhaler device or unable to
             perform acceptable spirometry.

          7. Clinically relevant abnormalities laboratory, ECG parameters or physical examination
             results at the screening evaluation that in the investigator's opinion, preclude study
             participation.

          8. Patients who intend to use any concomitant medication not permitted by this protocol
             or who have not undergone the required washout period for a particular prohibited
             medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Astbury, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#7</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3969&amp;filename=M-100977-25_CSRsynopsis.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <results_first_submitted>January 3, 2017</results_first_submitted>
  <results_first_submitted_qc>February 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 9 sites in Germany, 8 of which randomized patients</recruitment_details>
      <pre_assignment_details>Screening took place 14±2 days before randomization. After screening, eligible patients entered a run-in period to assess clinical stability. A total of 87 patients were screened, of whom 70 patients were assessed as eligible and randomized; 17 were not randomized due to screening failure (primarily non-fulfillment of inclusion/exclusion criteria)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence A</title>
          <description>Indacaterol 150 μg - LAS100977 10 μg - Placebo - LAS100977 0.625 μg - LAS100977 5 μg- LAS100977 2.5 μg</description>
        </group>
        <group group_id="P2">
          <title>Sequence B</title>
          <description>LAS100977 10 μg - LAS100977 0.625 μg - Indacaterol 150 μg - LAS100977 2.5 μg - Placebo - LAS100977 5 μg</description>
        </group>
        <group group_id="P3">
          <title>Sequence C</title>
          <description>LAS100977 0.625 μg - LAS100977 2.5 μg - LAS100977 10 μg - LAS100977 5 μg - Indacaterol 150 μg - Placebo</description>
        </group>
        <group group_id="P4">
          <title>Sequence D</title>
          <description>LAS100977 2.5 μg - LAS100977 5 μg - LAS100977 0.625 μg - Placebo - LAS100977 10 μg - Indacaterol 150 μg</description>
        </group>
        <group group_id="P5">
          <title>Sequence E</title>
          <description>LAS100977 5 μg - Placebo - LAS100977 2.5 μg - Indacaterol 150 μg - LAS100977 0.625 μg - LAS100977 10 μg</description>
        </group>
        <group group_id="P6">
          <title>Sequence F</title>
          <description>Placebo - Indacaterol 150 μg - LAS100977 5 μg - LAS100977 10 μg - LAS100977 2.5 μg - LAS100977 0.625 μg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Stability criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Stability criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Stability criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Population</title>
          <description>All patients who were randomized and received at least one dose of investigational medicinal product</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1 At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Day 2</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1 At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.035" spread="0.024"/>
                    <measurement group_id="O2" value="0.066" spread="0.024"/>
                    <measurement group_id="O3" value="0.168" spread="0.024"/>
                    <measurement group_id="O4" value="0.198" spread="0.024"/>
                    <measurement group_id="O5" value="0.223" spread="0.024"/>
                    <measurement group_id="O6" value="0.076" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.259</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.219</ci_lower_limit>
            <ci_upper_limit>0.298</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.233</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.194</ci_lower_limit>
            <ci_upper_limit>0.273</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.203</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.164</ci_lower_limit>
            <ci_upper_limit>0.242</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.062</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalised Forced Expiratory Volume in One Second (FEV1) Area Under the Curve</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Day 1</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalised Forced Expiratory Volume in One Second (FEV1) Area Under the Curve</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline in FEV1 AUC0-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.012"/>
                    <measurement group_id="O2" value="0.168" spread="0.021"/>
                    <measurement group_id="O3" value="0.243" spread="0.021"/>
                    <measurement group_id="O4" value="0.247" spread="0.021"/>
                    <measurement group_id="O5" value="0.288" spread="0.022"/>
                    <measurement group_id="O6" value="0.134" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline in FEV1 AUC0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.032" spread="0.013"/>
                    <measurement group_id="O2" value="0.121" spread="0.021"/>
                    <measurement group_id="O3" value="0.205" spread="0.022"/>
                    <measurement group_id="O4" value="0.222" spread="0.021"/>
                    <measurement group_id="O5" value="0.262" spread="0.024"/>
                    <measurement group_id="O6" value="0.104" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline in FEV1 AUC12-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.062" spread="0.016"/>
                    <measurement group_id="O2" value="0.077" spread="0.023"/>
                    <measurement group_id="O3" value="0.166" spread="0.024"/>
                    <measurement group_id="O4" value="0.196" spread="0.021"/>
                    <measurement group_id="O5" value="0.235" spread="0.021"/>
                    <measurement group_id="O6" value="0.073" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Up to Day 2</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.475" spread="0.059"/>
                    <measurement group_id="O2" value="1.506" spread="0.065"/>
                    <measurement group_id="O3" value="1.472" spread="0.062"/>
                    <measurement group_id="O4" value="1.483" spread="0.063"/>
                    <measurement group_id="O5" value="1.493" spread="0.065"/>
                    <measurement group_id="O6" value="1.488" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.08 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.013"/>
                    <measurement group_id="O2" value="0.044" spread="0.011"/>
                    <measurement group_id="O3" value="0.090" spread="0.011"/>
                    <measurement group_id="O4" value="0.085" spread="0.012"/>
                    <measurement group_id="O5" value="0.117" spread="0.016"/>
                    <measurement group_id="O6" value="0.103" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.25 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.013"/>
                    <measurement group_id="O2" value="0.087" spread="0.016"/>
                    <measurement group_id="O3" value="0.155" spread="0.015"/>
                    <measurement group_id="O4" value="0.161" spread="0.015"/>
                    <measurement group_id="O5" value="0.191" spread="0.019"/>
                    <measurement group_id="O6" value="0.132" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.5 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.015"/>
                    <measurement group_id="O2" value="0.126" spread="0.019"/>
                    <measurement group_id="O3" value="0.186" spread="0.018"/>
                    <measurement group_id="O4" value="0.202" spread="0.019"/>
                    <measurement group_id="O5" value="0.217" spread="0.021"/>
                    <measurement group_id="O6" value="0.150" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 1 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.015"/>
                    <measurement group_id="O2" value="0.151" spread="0.020"/>
                    <measurement group_id="O3" value="0.217" spread="0.021"/>
                    <measurement group_id="O4" value="0.218" spread="0.018"/>
                    <measurement group_id="O5" value="0.240" spread="0.023"/>
                    <measurement group_id="O6" value="0.156" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 2 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="0.016"/>
                    <measurement group_id="O2" value="0.166" spread="0.022"/>
                    <measurement group_id="O3" value="0.230" spread="0.021"/>
                    <measurement group_id="O4" value="0.245" spread="0.019"/>
                    <measurement group_id="O5" value="0.261" spread="0.024"/>
                    <measurement group_id="O6" value="0.161" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 3 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.014"/>
                    <measurement group_id="O2" value="0.201" spread="0.022"/>
                    <measurement group_id="O3" value="0.287" spread="0.022"/>
                    <measurement group_id="O4" value="0.274" spread="0.024"/>
                    <measurement group_id="O5" value="0.321" spread="0.023"/>
                    <measurement group_id="O6" value="0.184" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 4 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="0.014"/>
                    <measurement group_id="O2" value="0.225" spread="0.021"/>
                    <measurement group_id="O3" value="0.308" spread="0.023"/>
                    <measurement group_id="O4" value="0.308" spread="0.024"/>
                    <measurement group_id="O5" value="0.341" spread="0.173"/>
                    <measurement group_id="O6" value="0.179" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 6 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.017"/>
                    <measurement group_id="O2" value="0.216" spread="0.028"/>
                    <measurement group_id="O3" value="0.276" spread="0.024"/>
                    <measurement group_id="O4" value="0.276" spread="0.022"/>
                    <measurement group_id="O5" value="0.311" spread="0.031"/>
                    <measurement group_id="O6" value="0.135" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 8 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.016"/>
                    <measurement group_id="O2" value="0.169" spread="0.025"/>
                    <measurement group_id="O3" value="0.260" spread="0.025"/>
                    <measurement group_id="O4" value="0.263" spread="0.024"/>
                    <measurement group_id="O5" value="0.313" spread="0.025"/>
                    <measurement group_id="O6" value="0.124" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 12 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" spread="0.017"/>
                    <measurement group_id="O2" value="0.115" spread="0.025"/>
                    <measurement group_id="O3" value="0.189" spread="0.027"/>
                    <measurement group_id="O4" value="0.202" spread="0.027"/>
                    <measurement group_id="O5" value="0.271" spread="0.026"/>
                    <measurement group_id="O6" value="0.085" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 14 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.067" spread="0.020"/>
                    <measurement group_id="O2" value="0.099" spread="0.026"/>
                    <measurement group_id="O3" value="0.180" spread="0.026"/>
                    <measurement group_id="O4" value="0.214" spread="0.24"/>
                    <measurement group_id="O5" value="0.250" spread="0.026"/>
                    <measurement group_id="O6" value="0.087" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 23 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.066" spread="0.017"/>
                    <measurement group_id="O2" value="0.036" spread="0.023"/>
                    <measurement group_id="O3" value="0.134" spread="0.026"/>
                    <measurement group_id="O4" value="0.166" spread="0.022"/>
                    <measurement group_id="O5" value="0.211" spread="0.030"/>
                    <measurement group_id="O6" value="0.050" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 24 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.019"/>
                    <measurement group_id="O2" value="0.093" spread="0.023"/>
                    <measurement group_id="O3" value="0.184" spread="0.025"/>
                    <measurement group_id="O4" value="0.205" spread="0.021"/>
                    <measurement group_id="O5" value="0.236" spread="0.027"/>
                    <measurement group_id="O6" value="0.088" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 36 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.020"/>
                    <measurement group_id="O2" value="0.040" spread="0.024"/>
                    <measurement group_id="O3" value="0.104" spread="0.022"/>
                    <measurement group_id="O4" value="0.083" spread="0.023"/>
                    <measurement group_id="O5" value="0.116" spread="0.024"/>
                    <measurement group_id="O6" value="0.036" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Forced Expiratory Volume in One Second (FEV1) Values</title>
        <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Up to Day 2</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Forced Expiratory Volume in One Second (FEV1) Values</title>
          <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.475" spread="0.059"/>
                    <measurement group_id="O2" value="1.506" spread="0.065"/>
                    <measurement group_id="O3" value="1.472" spread="0.062"/>
                    <measurement group_id="O4" value="1.483" spread="0.063"/>
                    <measurement group_id="O5" value="1.493" spread="0.065"/>
                    <measurement group_id="O6" value="1.488" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.08 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.474" spread="0.060"/>
                    <measurement group_id="O2" value="1.549" spread="0.064"/>
                    <measurement group_id="O3" value="1.561" spread="0.064"/>
                    <measurement group_id="O4" value="1.568" spread="0.062"/>
                    <measurement group_id="O5" value="1.610" spread="0.065"/>
                    <measurement group_id="O6" value="1.585" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.25 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.482" spread="0.059"/>
                    <measurement group_id="O2" value="1.592" spread="0.064"/>
                    <measurement group_id="O3" value="1.627" spread="0.063"/>
                    <measurement group_id="O4" value="1.644" spread="0.064"/>
                    <measurement group_id="O5" value="1.673" spread="0.066"/>
                    <measurement group_id="O6" value="1.620" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.5 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.494" spread="0.060"/>
                    <measurement group_id="O2" value="1.640" spread="0.064"/>
                    <measurement group_id="O3" value="1.658" spread="0.063"/>
                    <measurement group_id="O4" value="1.685" spread="0.065"/>
                    <measurement group_id="O5" value="1.708" spread="0.067"/>
                    <measurement group_id="O6" value="1.683" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 1 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.485" spread="0.061"/>
                    <measurement group_id="O2" value="1.657" spread="0.066"/>
                    <measurement group_id="O3" value="1.688" spread="0.065"/>
                    <measurement group_id="O4" value="1.701" spread="0.067"/>
                    <measurement group_id="O5" value="1.733" spread="0.069"/>
                    <measurement group_id="O6" value="1.624" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 2 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.477" spread="0.061"/>
                    <measurement group_id="O2" value="1.671" spread="0.067"/>
                    <measurement group_id="O3" value="1.701" spread="0.067"/>
                    <measurement group_id="O4" value="1.729" spread="0.067"/>
                    <measurement group_id="O5" value="1.754" spread="0.068"/>
                    <measurement group_id="O6" value="1.642" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 3 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.494" spread="0.061"/>
                    <measurement group_id="O2" value="1.707" spread="0.069"/>
                    <measurement group_id="O3" value="1.758" spread="0.068"/>
                    <measurement group_id="O4" value="1.758" spread="0.069"/>
                    <measurement group_id="O5" value="1.814" spread="0.071"/>
                    <measurement group_id="O6" value="1.672" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 4 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.491" spread="0.061"/>
                    <measurement group_id="O2" value="1.730" spread="0.068"/>
                    <measurement group_id="O3" value="1.780" spread="0.068"/>
                    <measurement group_id="O4" value="1.790" spread="0.070"/>
                    <measurement group_id="O5" value="1.840" spread="0.073"/>
                    <measurement group_id="O6" value="1.677" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 6 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.477" spread="0.062"/>
                    <measurement group_id="O2" value="1.721" spread="0.070"/>
                    <measurement group_id="O3" value="1.748" spread="0.070"/>
                    <measurement group_id="O4" value="1.759" spread="0.069"/>
                    <measurement group_id="O5" value="1.804" spread="0.074"/>
                    <measurement group_id="O6" value="1.623" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 8 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.490" spread="0.062"/>
                    <measurement group_id="O2" value="1.674" spread="0.070"/>
                    <measurement group_id="O3" value="1.732" spread="0.070"/>
                    <measurement group_id="O4" value="1.746" spread="0.070"/>
                    <measurement group_id="O5" value="1.806" spread="0.073"/>
                    <measurement group_id="O6" value="1.612" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 12 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.428" spread="0.061"/>
                    <measurement group_id="O2" value="1.629" spread="0.069"/>
                    <measurement group_id="O3" value="1.660" spread="0.066"/>
                    <measurement group_id="O4" value="1.686" spread="0.068"/>
                    <measurement group_id="O5" value="1.761" spread="0.073"/>
                    <measurement group_id="O6" value="1.565" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 14 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.409" spread="0.061"/>
                    <measurement group_id="O2" value="1.605" spread="0.068"/>
                    <measurement group_id="O3" value="1.646" spread="0.068"/>
                    <measurement group_id="O4" value="1.693" spread="0.069"/>
                    <measurement group_id="O5" value="1.740" spread="0.072"/>
                    <measurement group_id="O6" value="1.585" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 23 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.411" spread="0.061"/>
                    <measurement group_id="O2" value="1.542" spread="0.068"/>
                    <measurement group_id="O3" value="1.606" spread="0.070"/>
                    <measurement group_id="O4" value="1.649" spread="0.070"/>
                    <measurement group_id="O5" value="1.701" spread="0.074"/>
                    <measurement group_id="O6" value="1.538" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 24 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.464" spread="0.062"/>
                    <measurement group_id="O2" value="1.599" spread="0.070"/>
                    <measurement group_id="O3" value="1.655" spread="0.071"/>
                    <measurement group_id="O4" value="1.688" spread="0.070"/>
                    <measurement group_id="O5" value="1.726" spread="0.073"/>
                    <measurement group_id="O6" value="1.576" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 36 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.464" spread="0.064"/>
                    <measurement group_id="O2" value="1.564" spread="0.068"/>
                    <measurement group_id="O3" value="1.575" spread="0.068"/>
                    <measurement group_id="O4" value="1.566" spread="0.069"/>
                    <measurement group_id="O5" value="1.607" spread="0.069"/>
                    <measurement group_id="O6" value="1.524" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Day 1</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.098" spread="0.016"/>
                    <measurement group_id="O2" value="0.290" spread="0.025"/>
                    <measurement group_id="O3" value="0.351" spread="0.022"/>
                    <measurement group_id="O4" value="0.350" spread="0.023"/>
                    <measurement group_id="O5" value="0.391" spread="0.024"/>
                    <measurement group_id="O6" value="0.263" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Forced Expiratory Volume in One Second (FEV1)</title>
        <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Day 1</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Forced Expiratory Volume in One Second (FEV1)</title>
          <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.2"/>
                    <measurement group_id="O2" value="3.4" spread="0.2"/>
                    <measurement group_id="O3" value="3.5" spread="0.2"/>
                    <measurement group_id="O4" value="3.7" spread="0.2"/>
                    <measurement group_id="O5" value="4.0" spread="0.2"/>
                    <measurement group_id="O6" value="2.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Forced Vital Capacity (FVC)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1 At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Day 2</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Vital Capacity (FVC)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1 At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.079" spread="0.044"/>
                    <measurement group_id="O2" value="0.067" spread="0.044"/>
                    <measurement group_id="O3" value="0.180" spread="0.044"/>
                    <measurement group_id="O4" value="0.217" spread="0.044"/>
                    <measurement group_id="O5" value="0.254" spread="0.044"/>
                    <measurement group_id="O6" value="0.088" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalised Forced Vital Capacity (FVC) Area Under the Curve</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Day 1</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalised Forced Vital Capacity (FVC) Area Under the Curve</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline in FVC AUC0-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.026"/>
                    <measurement group_id="O2" value="0.253" spread="0.037"/>
                    <measurement group_id="O3" value="0.297" spread="0.036"/>
                    <measurement group_id="O4" value="0.306" spread="0.034"/>
                    <measurement group_id="O5" value="0.372" spread="0.037"/>
                    <measurement group_id="O6" value="0.237" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline in FVC AUC0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034" spread="0.027"/>
                    <measurement group_id="O2" value="0.170" spread="0.036"/>
                    <measurement group_id="O3" value="0.253" spread="0.039"/>
                    <measurement group_id="O4" value="0.272" spread="0.035"/>
                    <measurement group_id="O5" value="0.328" spread="0.038"/>
                    <measurement group_id="O6" value="0.175" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline in FVC AUC12-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.096" spread="0.031"/>
                    <measurement group_id="O2" value="0.089" spread="0.039"/>
                    <measurement group_id="O3" value="0.208" spread="0.045"/>
                    <measurement group_id="O4" value="0.236" spread="0.039"/>
                    <measurement group_id="O5" value="0.284" spread="0.042"/>
                    <measurement group_id="O6" value="0.114" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Up to Day 2</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.165" spread="0.101"/>
                    <measurement group_id="O2" value="3.195" spread="0.104"/>
                    <measurement group_id="O3" value="3.137" spread="0.102"/>
                    <measurement group_id="O4" value="3.153" spread="0.094"/>
                    <measurement group_id="O5" value="3.212" spread="0.108"/>
                    <measurement group_id="O6" value="3.190" spread="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.08 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" spread="0.026"/>
                    <measurement group_id="O2" value="0.098" spread="0.027"/>
                    <measurement group_id="O3" value="0.166" spread="0.034"/>
                    <measurement group_id="O4" value="0.178" spread="0.027"/>
                    <measurement group_id="O5" value="0.267" spread="0.040"/>
                    <measurement group_id="O6" value="0.221" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.25 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.027"/>
                    <measurement group_id="O2" value="0.140" spread="0.033"/>
                    <measurement group_id="O3" value="0.193" spread="0.037"/>
                    <measurement group_id="O4" value="0.212" spread="0.033"/>
                    <measurement group_id="O5" value="0.264" spread="0.036"/>
                    <measurement group_id="O6" value="0.192" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.5 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127" spread="0.085"/>
                    <measurement group_id="O2" value="0.191" spread="0.035"/>
                    <measurement group_id="O3" value="0.232" spread="0.037"/>
                    <measurement group_id="O4" value="0.263" spread="0.036"/>
                    <measurement group_id="O5" value="0.277" spread="0.037"/>
                    <measurement group_id="O6" value="0.246" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 1 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.029"/>
                    <measurement group_id="O2" value="0.242" spread="0.041"/>
                    <measurement group_id="O3" value="0.263" spread="0.043"/>
                    <measurement group_id="O4" value="0.241" spread="0.036"/>
                    <measurement group_id="O5" value="0.289" spread="0.042"/>
                    <measurement group_id="O6" value="0.246" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 2 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.035"/>
                    <measurement group_id="O2" value="0.224" spread="0.041"/>
                    <measurement group_id="O3" value="0.0269" spread="0.040"/>
                    <measurement group_id="O4" value="0.300" spread="0.035"/>
                    <measurement group_id="O5" value="0.303" spread="0.042"/>
                    <measurement group_id="O6" value="0.244" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 3 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.026"/>
                    <measurement group_id="O2" value="0.248" spread="0.044"/>
                    <measurement group_id="O3" value="0.338" spread="0.041"/>
                    <measurement group_id="O4" value="0.325" spread="0.041"/>
                    <measurement group_id="O5" value="0.392" spread="0.039"/>
                    <measurement group_id="O6" value="0.274" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 4 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" spread="0.030"/>
                    <measurement group_id="O2" value="0.297" spread="0.042"/>
                    <measurement group_id="O3" value="0.379" spread="0.039"/>
                    <measurement group_id="O4" value="0.337" spread="0.042"/>
                    <measurement group_id="O5" value="0.402" spread="0.035"/>
                    <measurement group_id="O6" value="0.254" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 6 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.034"/>
                    <measurement group_id="O2" value="0.340" spread="0.048"/>
                    <measurement group_id="O3" value="0.327" spread="0.044"/>
                    <measurement group_id="O4" value="0.348" spread="0.042"/>
                    <measurement group_id="O5" value="0.415" spread="0.044"/>
                    <measurement group_id="O6" value="0.231" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 8 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" spread="0.037"/>
                    <measurement group_id="O2" value="0.263" spread="0.045"/>
                    <measurement group_id="O3" value="0.309" spread="0.044"/>
                    <measurement group_id="O4" value="0.335" spread="0.040"/>
                    <measurement group_id="O5" value="0.425" spread="0.050"/>
                    <measurement group_id="O6" value="0.266" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 12 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.035" spread="0.038"/>
                    <measurement group_id="O2" value="0.198" spread="0.048"/>
                    <measurement group_id="O3" value="0.259" spread="0.046"/>
                    <measurement group_id="O4" value="0.272" spread="0.050"/>
                    <measurement group_id="O5" value="0.329" spread="0.048"/>
                    <measurement group_id="O6" value="0.182" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 14 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.110" spread="0.043"/>
                    <measurement group_id="O2" value="0.107" spread="0.047"/>
                    <measurement group_id="O3" value="0.236" spread="0.050"/>
                    <measurement group_id="O4" value="0.266" spread="0.043"/>
                    <measurement group_id="O5" value="0.315" spread="0.046"/>
                    <measurement group_id="O6" value="0.148" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 23 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.093" spread="0.037"/>
                    <measurement group_id="O2" value="0.039" spread="0.042"/>
                    <measurement group_id="O3" value="0.153" spread="0.050"/>
                    <measurement group_id="O4" value="0.187" spread="0.044"/>
                    <measurement group_id="O5" value="0.244" spread="0.051"/>
                    <measurement group_id="O6" value="0.063" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 24 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.076" spread="0.035"/>
                    <measurement group_id="O2" value="0.090" spread="0.039"/>
                    <measurement group_id="O3" value="0.186" spread="0.038"/>
                    <measurement group_id="O4" value="0.207" spread="0.039"/>
                    <measurement group_id="O5" value="0.243" spread="0.046"/>
                    <measurement group_id="O6" value="0.100" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 36 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.037"/>
                    <measurement group_id="O2" value="0.063" spread="0.040"/>
                    <measurement group_id="O3" value="0.114" spread="0.045"/>
                    <measurement group_id="O4" value="0.059" spread="0.038"/>
                    <measurement group_id="O5" value="0.140" spread="0.040"/>
                    <measurement group_id="O6" value="0.084" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Forced Vital Capacity (FVC) Values</title>
        <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Up to Day 2</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Forced Vital Capacity (FVC) Values</title>
          <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.165" spread="0.101"/>
                    <measurement group_id="O2" value="3.195" spread="0.104"/>
                    <measurement group_id="O3" value="3.137" spread="0.102"/>
                    <measurement group_id="O4" value="3.153" spread="0.094"/>
                    <measurement group_id="O5" value="3.212" spread="0.108"/>
                    <measurement group_id="O6" value="3.190" spread="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.08 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.205" spread="0.106"/>
                    <measurement group_id="O2" value="3.293" spread="0.112"/>
                    <measurement group_id="O3" value="3.318" spread="0.105"/>
                    <measurement group_id="O4" value="3.331" spread="0.100"/>
                    <measurement group_id="O5" value="3.479" spread="0.116"/>
                    <measurement group_id="O6" value="3.418" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.25 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.169" spread="0.098"/>
                    <measurement group_id="O2" value="3.335" spread="0.109"/>
                    <measurement group_id="O3" value="3.329" spread="0.102"/>
                    <measurement group_id="O4" value="3.365" spread="0.100"/>
                    <measurement group_id="O5" value="3.455" spread="0.111"/>
                    <measurement group_id="O6" value="3.382" spread="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.5 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.292" spread="0.126"/>
                    <measurement group_id="O2" value="3.399" spread="0.110"/>
                    <measurement group_id="O3" value="3.368" spread="0.105"/>
                    <measurement group_id="O4" value="3.417" spread="0.101"/>
                    <measurement group_id="O5" value="3.488" spread="0.112"/>
                    <measurement group_id="O6" value="3.441" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 1 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.217" spread="0.104"/>
                    <measurement group_id="O2" value="3.436" spread="0.110"/>
                    <measurement group_id="O3" value="3.400" spread="0.107"/>
                    <measurement group_id="O4" value="3.394" spread="0.102"/>
                    <measurement group_id="O5" value="3.501" spread="0.114"/>
                    <measurement group_id="O6" value="3.415" spread="0.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 2 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.201" spread="0.101"/>
                    <measurement group_id="O2" value="3.418" spread="0.111"/>
                    <measurement group_id="O3" value="3.406" spread="0.107"/>
                    <measurement group_id="O4" value="3.454" spread="0.102"/>
                    <measurement group_id="O5" value="3.514" spread="0.109"/>
                    <measurement group_id="O6" value="3.415" spread="0.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 3 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.185" spread="0.099"/>
                    <measurement group_id="O2" value="3.443" spread="0.109"/>
                    <measurement group_id="O3" value="3.475" spread="0.106"/>
                    <measurement group_id="O4" value="3.478" spread="0.103"/>
                    <measurement group_id="O5" value="3.603" spread="0.116"/>
                    <measurement group_id="O6" value="3.464" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 4 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.181" spread="0.101"/>
                    <measurement group_id="O2" value="3.492" spread="0.108"/>
                    <measurement group_id="O3" value="3.516" spread="0.103"/>
                    <measurement group_id="O4" value="3.478" spread="0.099"/>
                    <measurement group_id="O5" value="3.608" spread="0.114"/>
                    <measurement group_id="O6" value="3.448" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 6 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.220" spread="0.097"/>
                    <measurement group_id="O2" value="3.535" spread="0.118"/>
                    <measurement group_id="O3" value="3.464" spread="0.109"/>
                    <measurement group_id="O4" value="3.501" spread="0.109"/>
                    <measurement group_id="O5" value="3.626" spread="0.119"/>
                    <measurement group_id="O6" value="3.421" spread="0.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 8 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.232" spread="0.103"/>
                    <measurement group_id="O2" value="3.458" spread="0.114"/>
                    <measurement group_id="O3" value="3.445" spread="0.110"/>
                    <measurement group_id="O4" value="3.488" spread="0.107"/>
                    <measurement group_id="O5" value="3.636" spread="0.122"/>
                    <measurement group_id="O6" value="3.469" spread="0.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 12 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.130" spread="0.105"/>
                    <measurement group_id="O2" value="3.406" spread="0.118"/>
                    <measurement group_id="O3" value="3.396" spread="0.108"/>
                    <measurement group_id="O4" value="3.425" spread="0.105"/>
                    <measurement group_id="O5" value="3.534" spread="0.119"/>
                    <measurement group_id="O6" value="3.367" spread="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 14 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.055" spread="0.107"/>
                    <measurement group_id="O2" value="3.302" spread="0.112"/>
                    <measurement group_id="O3" value="3.359" spread="0.111"/>
                    <measurement group_id="O4" value="3.411" spread="0.107"/>
                    <measurement group_id="O5" value="3.520" spread="0.118"/>
                    <measurement group_id="O6" value="3.348" spread="0.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 23 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.075" spread="0.108"/>
                    <measurement group_id="O2" value="3.233" spread="0.111"/>
                    <measurement group_id="O3" value="3.290" spread="0.107"/>
                    <measurement group_id="O4" value="3.341" spread="0.107"/>
                    <measurement group_id="O5" value="3.448" spread="0.117"/>
                    <measurement group_id="O6" value="3.257" spread="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 24 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.095" spread="0.103"/>
                    <measurement group_id="O2" value="3.284" spread="0.109"/>
                    <measurement group_id="O3" value="3.323" spread="0.104"/>
                    <measurement group_id="O4" value="3.360" spread="0.102"/>
                    <measurement group_id="O5" value="3.447" spread="0.110"/>
                    <measurement group_id="O6" value="3.295" spread="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 36 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.145" spread="0.102"/>
                    <measurement group_id="O2" value="3.289" spread="0.109"/>
                    <measurement group_id="O3" value="3.251" spread="0.108"/>
                    <measurement group_id="O4" value="3.212" spread="0.102"/>
                    <measurement group_id="O5" value="3.345" spread="0.110"/>
                    <measurement group_id="O6" value="3.274" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Forced Vital Capacity (FVC)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Day 1</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Forced Vital Capacity (FVC)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.332" spread="0.050"/>
                    <measurement group_id="O2" value="0.484" spread="0.050"/>
                    <measurement group_id="O3" value="0.523" spread="0.050"/>
                    <measurement group_id="O4" value="0.532" spread="0.050"/>
                    <measurement group_id="O5" value="0.575" spread="0.050"/>
                    <measurement group_id="O6" value="0.470" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Forced Vital Capacity (FVC)</title>
        <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
        <time_frame>Day 1</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Forced Vital Capacity (FVC)</title>
          <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.3"/>
                    <measurement group_id="O2" value="3.6" spread="0.3"/>
                    <measurement group_id="O3" value="3.4" spread="0.2"/>
                    <measurement group_id="O4" value="3.1" spread="0.2"/>
                    <measurement group_id="O5" value="3.6" spread="0.3"/>
                    <measurement group_id="O6" value="2.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inspiratory Capacity (IC)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS</description>
        <time_frame>Up to Day 2</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inspiratory Capacity (IC)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.240" spread="0.082"/>
                    <measurement group_id="O2" value="2.239" spread="0.078"/>
                    <measurement group_id="O3" value="2.234" spread="0.075"/>
                    <measurement group_id="O4" value="2.254" spread="0.077"/>
                    <measurement group_id="O5" value="2.237" spread="0.077"/>
                    <measurement group_id="O6" value="2.246" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 4 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.037"/>
                    <measurement group_id="O2" value="0.260" spread="0.039"/>
                    <measurement group_id="O3" value="0.239" spread="0.040"/>
                    <measurement group_id="O4" value="0.316" spread="0.043"/>
                    <measurement group_id="O5" value="0.370" spread="0.043"/>
                    <measurement group_id="O6" value="0.215" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 24 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" spread="0.040"/>
                    <measurement group_id="O2" value="0.110" spread="0.037"/>
                    <measurement group_id="O3" value="0.157" spread="0.037"/>
                    <measurement group_id="O4" value="0.174" spread="0.038"/>
                    <measurement group_id="O5" value="0.273" spread="0.046"/>
                    <measurement group_id="O6" value="0.136" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Inspiratory Capacity (IC) Values</title>
        <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS</description>
        <time_frame>Up to Day 2</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.625 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 2.5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 5 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 10 μg</title>
            <description>Single dose administered by inhalation from the Genuair® device</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 150 μg</title>
            <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Inspiratory Capacity (IC) Values</title>
          <description>At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.240" spread="0.082"/>
                    <measurement group_id="O2" value="2.239" spread="0.078"/>
                    <measurement group_id="O3" value="2.234" spread="0.075"/>
                    <measurement group_id="O4" value="2.254" spread="0.077"/>
                    <measurement group_id="O5" value="2.237" spread="0.077"/>
                    <measurement group_id="O6" value="2.246" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 4 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.279" spread="0.076"/>
                    <measurement group_id="O2" value="2.504" spread="0.081"/>
                    <measurement group_id="O3" value="2.473" spread="0.083"/>
                    <measurement group_id="O4" value="2.548" spread="0.088"/>
                    <measurement group_id="O5" value="2.623" spread="0.088"/>
                    <measurement group_id="O6" value="2.447" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 24 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.203" spread="0.074"/>
                    <measurement group_id="O2" value="2.374" spread="0.082"/>
                    <measurement group_id="O3" value="2.398" spread="0.085"/>
                    <measurement group_id="O4" value="2.402" spread="0.081"/>
                    <measurement group_id="O5" value="2.543" spread="0.086"/>
                    <measurement group_id="O6" value="2.380" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 (±2) days after the last investigational medicinal product administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Single dose administered by inhalation from the Genuair® device and the Breezhaler® inhaler</description>
        </group>
        <group group_id="E2">
          <title>LAS100977 0.625 μg</title>
          <description>Single dose administered by inhalation from the Genuair® device</description>
        </group>
        <group group_id="E3">
          <title>LAS100977 2.5 μg</title>
          <description>Single dose administered by inhalation from the Genuair® device</description>
        </group>
        <group group_id="E4">
          <title>LAS100977 5 μg</title>
          <description>Single dose administered by inhalation from the Genuair® device</description>
        </group>
        <group group_id="E5">
          <title>LAS100977 10 μg</title>
          <description>Single dose administered by inhalation from the Genuair® device</description>
        </group>
        <group group_id="E6">
          <title>Indacaterol 150 μg</title>
          <description>Single dose administered by inhalation from the Breezhaler® inhaler</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subjected to revision and written agreement between the investigator and Sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

